Synapse - Department of Medicine

Results (39622)

TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2

Meeting Abstract

Tung, N. M.; Robson, M. E.; Nanda, R.; Li, T.; Vinayak, S.; Shah, P. D.; Khoury, K.; Kimmick, G. G.; Santa-Maria, C. A.; Brufsky, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Phase 1 study of NB003, a broad-spectrum KIT/PDGFRα inhibitor, in patients with advanced gastrointestinal stromal tumors (GIST)

Meeting Abstract

Li, J.; Chi, P.; Kang, Y. K.; Cao, H.; George, S.; Zhang, J.; Zhang, J.; Hu, K.; Zhang, L. J.; Xu, Y. H.
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Outcomes of larotrectinib compared with real-world data from non-TRK inhibitor therapies in patients with TRK fusion cancer: VICTORIA study

Meeting Abstract

Brose, M. S.; Westphalen, C. B.; Kehl, K. L.; Pan, X.; Bernard-Gauthier, V.; Kurtinecz, M.; Guo, H.; Aris, V.; Brett, N. R.; Majdi, A. A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with (177)Lu-PSMA-617 versus change of ARPI in PSMAfore

Meeting Abstract

De Bono, J. S.; Morris, M. J.; Sartor, O.; Wei, X. X.; Fizazi, K.; Herrmann, K.; Piulats, J. M.; Mahammedi, H.; Logothetis, C.; George, D. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

LIBERTAS: A degendered and transgender-inclusive phase 3 study of apalutamide (APA) plus intermittent vs continuous androgen deprivation therapy (ADT) in participants (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)

Meeting Abstract

Azad, A.; Musto, C.; Netanel, S.; Zhang, T.; Rathkopf, D. E.; Badillo, M. A.; Dong, Q.; Morgans, A. K.; Runcie, K.; Dos Santos, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202)

Meeting Abstract

Barlesi, F.; Felip, E.; Popat, S.; Solomon, B. J.; Wolf, J.; Li, B. T.; Wu, Y. L.; Kerr, K.; Akamatsu, H.; Camidge, D. R.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2- breast cancer (BC)

Meeting Abstract

Juric, D.; Patel, M. R.; Duska, L. R.; Jhaveri, K. L.; Henick, B. S.; Matulonis, U. A.; Munster, P. N.; Birrer, M. J.; Moore, K. N.; Curigliano, G.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Enfortumab vedotin (EV) in previously treated gastric/esophageal cancers cohorts of EV-202

Meeting Abstract

Muro, K.; Chin, K.; Maron, S. B.; Braiteh, F. S.; Mitani, S.; Hara, H.; Kuboki, Y.; Mulcahy, M. F.; Baranda, J. C.; Gardner, F. P.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Meeting Abstract

Andre, F.; Hamilton, E. P.; Loi, S.; Anders, C. K.; Schmid, P.; Stroyakovskiy, D.; Villanueva, R.; Pedrini, J. L.; Doval, D. C.; Zurawski, B.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Epcoritamab with rituximab + lenalidomide (R(2)) in previously untreated (1L) follicular lymphoma (FL) and epcoritamab maintenance in FL: EPCORE NHL-2 arms 6 and 7

Meeting Abstract

Lori, L. A.; Falchi, L.; Vermaat, J. S. P.; Musuraca, G.; Belada, D.; Nijland, M.; Christensen, J. H.; Offner, F.; Hoehn, D.; Marek, J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save